Psoriatic Arthritis Trial, Recruiting NCT04876781 Sponsor: Pfizer Condition: Psoriatic Arthritis
Back to Psoriatic Arthritis

Psoriatic Arthritis Trial, Recruiting

NCT04876781
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are an adult (18 or older) taking Xeljanz® XR as prescribed for moderate to severe rheumatoid arthritis, and a previous treatment called methotrexate did not work well enough for you or you could not tolerate it
  • You are an adult (18 or older) taking Xeljanz® XR together with methotrexate for active psoriatic arthritis, and a previous arthritis medication did not work well enough for you or you could not tolerate it
  • You are an adult (18 or older) taking Xeljanz® XR for active ankylosing spondylitis (a type of spinal arthritis), and standard treatments have not worked well enough for you
  • You are aged 65 or older, have a high risk of heart problems, or have a higher risk of cancer, and your doctor has decided Xeljanz® XR is appropriate after other treatments have not worked or were not tolerated
  • You previously took the standard Xeljanz 5mg tablet and have switched to the extended-release version, Xeljanz® XR
  • You (or your legal representative) have read, understood, and signed a consent form agreeing to take part in the study

Who may not be able to join:

  • You have ever had a serious allergic reaction to any ingredient in this medication
  • You currently have a serious infection (such as blood poisoning) or any active infection, even a mild localised one
  • You currently have active tuberculosis (TB)
  • You have severe liver problems or disease
  • Your white blood cell count (a measure of infection-fighting cells called neutrophils) is too low, specifically below 1,000 cells/mm³ (confirm with trial site)
  • Your lymphocyte count (another type of immune cell) is too low, specifically below 500 cells/mm³ (confirm with trial site)
  • Your haemoglobin level (a measure of red blood cells that carry oxygen) is too low, specifically below 9 g/dL (confirm with trial site)
  • You are pregnant or think you might be pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
12 January 2022
Est. completion
22 September 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Number of Participants With Treatment Emergent Adverse Events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov